Journal of the Japan Diabetes Society
Online ISSN : 1881-588X
Print ISSN : 0021-437X
ISSN-L : 0021-437X
Search
Advanced search
OR
Browse
Search
Volume 53, Issue 3
Displaying 1-7 of 7 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Original Articles
  • Efficacy and Safety of Switching from Premix Twice Daily Injection to Sulfonylurea and Once Daily Insulin Glargine in Japanese Type 2 Diabetes (JUN-LAN Study 8)
    Nayumi Shigihara, Motoyuki Tamaki, Hiromasa Goto, Junko Kawai, Yoshio ...
    2010 Volume 53 Issue 3 Pages 157-161
    Published: 2010
    Released on J-STAGE: May 14, 2010
    DOIhttps://doi.org/10.11213/tonyobyo.53.157
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We have evaluated the efficacy and safety of switching from premix twice daily injection to basal supported oral therapy (BOT) sulfonylurea with once daily glargine in Japanese type 2 diabetes. Those whose HbA1C was ≥7.0% over 6 months with premix twice daily injection underwent combined therapy with sulfonylurea and once daily insulin glargine at bed time or morning. After 24 weeks, mean HbA1C improved significantly from 8.26±1.14% to 7.70±0.78%, as did fasting blood glucose from 155.1±38.7 mg/dl to 120.6±24.1 mg/dl. Total daily insulin dose decreased significantly from 0.42±0.20 U/kg of premix insulin to 0.34±0.19 U/kg of glargine. Hypoglycemic episodes in 5 subjects were mediated after decreasing the glimepiride dose. These results suggested that switching from premix twice daily to BOT was effective and safe, but more intensive therapy such as step-up bolus insulin addition to BOT was required for most subjects to be treated to the target.
    View full abstract
    Download PDF (454K)
  • Simultaneous Pancreas-kidney Transplantation Improving Diabetic Neuropathy, Macroangiopathy, and Quality of Life in those with Type 1 Diabetes Mellitus and End-stage Renal Failure in Japan
    Masanori Iwase, Atsushi Sugitani, Hidehisa Kitada, Masao Tanaka, Mitsu ...
    2010 Volume 53 Issue 3 Pages 162-168
    Published: 2010
    Released on J-STAGE: May 14, 2010
    DOIhttps://doi.org/10.11213/tonyobyo.53.162
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Simultaneous pancreas-kidney transplantation (SPK) is used to treat those with type 1 diabetes mellitus and end-stage renal failure in Japan, mediating diabetic complications and quality of life (QOL). The serious shortage of brain-death donors in Japan has, however, prevented SPK benefits from being verified. We studied SPK effects on diabetic neuropathy, macroangiopathy, and QOL in 13 SPK recipients with a mean age of 40 years, mean diabetes duration of 23 years, and mean hemodialysis of 6 years at mean 2.6 years after transplantation. Posttransplantation motor nerve conduction velocity, heart rate variability, and gastric emptying improved significantly and were significantly better than those in those waiting for treatment. Left ventricular hypertrophy and pulse wave velocity improved after transplantation. QOL evaluated by Short-Form 36 was better physically and mentally than that in those waiting and further improved 2 years later, while QOL in those waiting patients remained severely impaired. We found that SPK improved diabetic neuropathy, macroangiopathy, and QOL in those with type 1 diabetes mellitus and end-stage renal failure in Japan.
    View full abstract
    Download PDF (1013K)
Case Reports
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top